Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation

Takehiko Mori, Jun Kato, Akiko Yamane, Yoshinobu Aisa, Yusuke Kawata, Mayu Ichimura, Chiaki Tsuneyama, Tomoko Yashima, Yoko Ogawa, Kazuo Tsubota, Naoyuki Shigematsu, Takayuki Shimizu, Shinichiro Okamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalInternational Journal of Hematology
Volume94
Issue number3
DOIs
Publication statusPublished - 2011 Sep

Fingerprint

Conjunctivitis
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Cytarabine
Incidence
Ophthalmic Solutions
Adrenal Cortex Hormones

Keywords

  • Eye rinse
  • High-dose cytarabine
  • Kerato-conjunctivitis
  • Topical corticosteroid
  • Total body irradiation

ASJC Scopus subject areas

  • Hematology

Cite this

@article{cb9ee72e305d4fb283cfd444e7dc9f87,
title = "Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation",
abstract = "We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4{\%}) and 5 patients (21.7{\%}), respectively. These incidences were significantly lower than those [35 (66.0{\%}) and 41 (77.4{\%})] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.",
keywords = "Eye rinse, High-dose cytarabine, Kerato-conjunctivitis, Topical corticosteroid, Total body irradiation",
author = "Takehiko Mori and Jun Kato and Akiko Yamane and Yoshinobu Aisa and Yusuke Kawata and Mayu Ichimura and Chiaki Tsuneyama and Tomoko Yashima and Yoko Ogawa and Kazuo Tsubota and Naoyuki Shigematsu and Takayuki Shimizu and Shinichiro Okamoto",
year = "2011",
month = "9",
doi = "10.1007/s12185-011-0912-x",
language = "English",
volume = "94",
pages = "261--265",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Kato, Jun

AU - Yamane, Akiko

AU - Aisa, Yoshinobu

AU - Kawata, Yusuke

AU - Ichimura, Mayu

AU - Tsuneyama, Chiaki

AU - Yashima, Tomoko

AU - Ogawa, Yoko

AU - Tsubota, Kazuo

AU - Shigematsu, Naoyuki

AU - Shimizu, Takayuki

AU - Okamoto, Shinichiro

PY - 2011/9

Y1 - 2011/9

N2 - We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.

AB - We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.

KW - Eye rinse

KW - High-dose cytarabine

KW - Kerato-conjunctivitis

KW - Topical corticosteroid

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=80855137978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855137978&partnerID=8YFLogxK

U2 - 10.1007/s12185-011-0912-x

DO - 10.1007/s12185-011-0912-x

M3 - Article

C2 - 21853271

AN - SCOPUS:80855137978

VL - 94

SP - 261

EP - 265

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -